Introduction
AL amyloidosis is caused by misfolding, aggregation and deposition of certain monoclonal immunoglobulin light chains as extracellular insoluble fibrillar deposits that stain with Congo red and produce pathognomonic red-green birefringence when viewed in cross polarised light. The age adjusted incidence of AL amyloidosis is 5.1-12.8 per million patient years 1 ,
and it is usually associated with very subtle clonal plasma cell dyscrasias 2 that are usually best monitored by the very sensitive serum free light chain assay. 3 When a whole paraprotein can be identified, it is much more commonly either IgG or IgA than IgM. 4 Indeed, in contrast to the 20% frequency of IgM paraproteinaemia among patients with monoclonal gammopathy of uncertain significance (MGUS), 5 remarkably few patients with AL amyloidosis consequent on IgM paraproteinaemia have been reported 6 . Only 50 such patients were identified among the very large experience of AL amyloidosis at the Mayo clinic over a 22 year period. 7, 8 Other reports are of single individuals or small case series. 9, 10 The response to chemotherapy in this rare group of patients is even less well reported.
We report here the manifestations of amyloidosis and characteristics of the underlying clonal disease at diagnosis, and clinical outcome following various types of chemotherapy in 103 consecutive patients with AL amyloidosis complicating IgM paraproteinaemia, who were evaluated in our centre between 1988 and 2006.
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Materials and Methods

Patients, Diagnosis and Protocol
All patients with AL amyloidosis in whom a single paraprotein of IgM class had been demonstrated in the serum or urine by electrophoresis or immunofixation, who were first seen at the UK National Amyloidosis Centre (NAC) between 1988 and 2006, were identified retrospectively from the NAC database.
The presence of amyloid was confirmed by characteristic Congo red staining of a tissue biopsy and/or by a diagnostic SAP scan in all cases. AL type amyloidosis was confirmed by immunohistochemical staining that included a panel of antibodies against known amyloid fibrils proteins 11 and and exclusion of hereditary amyloidosis by demonstration of wild-type sequence for the genes encoding known hereditary amyloidogenic proteins. 12 Myeloma and MGUS were defined according to previously published criteria. 13 IgM MGUS was defined according to the criteria described by Baldini et al. 6 All patients underwent protocolized assessments scheduled at six monthly intervals until six months after the end of chemotherapy and then at Amyloidotic organ involvement and response were defined according to the international consensus criteria 17 Heart, liver, kidneys, gastrointestinal tract, nerves (autonomic and/or peripheral), lungs and soft tissue (lymphnode, tongue, muscles, factor X deficiency or any other) were counted as individual organs. Since lymph node involvement was a prominent feature of the current series, these were also reported separately. All organ responses (as defined by the international consensus criteria) 17 were assessed 6 months following initial chemotherapy or before the patient received another regimen.
All patients underwent 123 I-labeled serum amyloid P component (SAP)
scintigraphy, and serial studies were used to quantitatively measure whole body amyloid load, as previously described. 
Treatment and response
Haematological response to first line chemotherapy was evaluable in 77 (75%) patients, in 75 cases by conventional means, and in 22 patients by FLC assay. Eight patients were not treated, and insufficient data were available to determine response in 18 patients. FLCs were not evaluable in 55/77 patients due to either a pre-treatment aberrant FLC concentration of < 100mg/l, or the ratio being normal.
A variety of chemotherapy regimens were used and are listed in Table   2 . Patients received a median of four cycles (range 2-9) chemotherapy. Twenty one (27%) patients without bone marrow plasma cell infiltrate received a regime typically used for treatment of plasma cell disorders with only three patients having a partial response (two treated with VAD and one with CTD).
The haematological responses are shown in Table 3 
Survival
There was no significant difference in the overall survival of patients with a lymphoid, lymphoplasmacytoid, plasma cells or normal/unknown infiltrate in the bone marrow (median Kaplan-Meier estimate of 47 months, 49 months, 51 months, 39 months respectively; log rank p=0.9). Only one of the deaths was directly due to the underlying lymphoma (high grade transformation). The Kaplan-Meier estimated median OS for the whole cohort from diagnosis was 49 months (Figure 2A ). Although the difference did not attain statistically significance, potentially reflecting the relatively small numbers of patients, the estimated 10 year survival for non-responders was <10% compared to >50% for responders, with the survival curves diverging at ~50 months ( Figure 2B ). The Kaplan-Meier estimated OS was 44 months for the 26 patients who were not treated or were not evaluable for treatment response.
Estimated median survival for patients with single organ involvement was 84 months compared to 26 and 19 months respectively for those with two or three involved organs (log rank, p = 0.003). The estimated 10 year survival among patients with ECOG performance status of ≤ 1 before treatment was >90% ( Figure 2C ). The various factors associated with survival are detailed in Table 4 , of which on univariate analysis, ECOG performance status, number of organs involved by amyloid, and presence of amyloid deposits in the heart or liver were significant. On multivariate analysis, only performance status and liver involvement were significant (p<0.0001, RR 3.7 and p=0.018, RR 2.2 respectively).
For , the largest reported series of IgM associated amyloidosis is 50 patients from the Mayo Clinic in whom treatment outcomes have not been clearly reported. 7 The current series of 103 patients accounted for 6%
of patients with confirmed AL amyloidosis seen at the UK NAC between 1988-2006, similar to the 5% frequency at the Mayo Clinic. 4 In our series, 54% of patients had ≥ 2 organ involvement by amyloid, most frequently the kidneys (53%) followed by the heart (35%), similar to the large previous Mayo series of patients with AL associated with non-IgM monoclonal proteins. 4 Lymph node involvement is uncommon in AL amyloidosis associated with non-IgM paraproteins 4 but was evident in 21% of patients in our series ( Figure 3 ).
Conversely, peripheral neuropathy was less common at presentation, in just 3%, than in previously reported non-IgM series. 4 32 The same variability is likely to exist in IgM associated amyloidosis patients -there was a suggestion that lymphoplasmacytoid morphology was the commonest followed by lymphoid but this will need further prospective study for confirmation. However, it is important to recognize this marked variability of the underlying clonal disorder in these cases -which contrasts from those with AL amyloidosis in general where the underlying clonal cell population is usually a plasma cell dyscrasia -a fact that is not widely recognized outside of specialized centres. IgM amyloidosis patients often do not undergo full immunophenotyping to characterize the lymphoid clone -investigations being focused towards characterizing the plasma cell disorder. A fact also seen in the current series and hence, in some cases, leading to less than appropriate The latter, however, compares poorly with a widely reported CR rate of 40% following SCT in non-IgM amyloidosis 33 , but is in keeping with the relatively low complete response rates following SCT in WM compared with myeloma. 34 35 The wide variety of chemotherapy regimens received by our patients reflects the lack of standardization of treatment in this condition and we emphasize the critical need to recognize the distinct underlying clonal disorder in this sub-group of patients from that of AL amyloidosis in general for selection of regimens appropriate for a lymphoid clonal disorder rather than a plasma cell disorder. The overall haematologic response rate to initial treatment was poor (32%) -some of which may represent the fact that 27% patients received regimens which are not very effective in lymphoproliferative disorders. The small number of responding cases in each group limits the interpretation of response data in relation to the underlying disorder. It was encouraging that patients who received a combination regime or purine analogues with/without rituximab (defined here as combination chemotherapy such as CHOP or similar combinations, purine analogues, or rituximab or its combination with other agents) had a three-fold higher response rate than those single agent oral alkylators or thalidomide and its combinations. These
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given that a fifth of patients can expect a CR following the more recent combination chemotherapy for non-IgM amyloidosis. These findings are not surprising since CR is known to be rare in WM or CLL treated with alkylators, 41 single agent purine analogues 42, 43 or single agent rituximab. 44 .
These findings and also the fact the haematological responses in the current series did not translate into survival improvement identify an urgent need to study more effective chemo-immunotherapeutic or other novel treatment approaches.
Median overall survival for IgM amyloidosis was about 2 years in the 1993 Mayo series 7 , similar to that reported in non-IgM associated AL amyloidosis at the time. 4 There was no significant difference in the overall survival according to the underlying disorder which is in keeping with the fact that most cases had a low grade disorder with progressive lymphoma being the actual cause of death in only one case. Survival in AL amyloidosis in general appears to be improving, and median survival of 600 AL patients assessed at the UK National Amyloidosis Centre (NAC) over the last decade has been 3.3 years (NAC unpublished data), a value comparable with the
ECOG performance status at presentation was the most significant single factor associated with survival in the current cohort, and patients with single organ involvement by amyloid had a notably good prognosis. Only four patients had advanced cardiac amyloidosis in the current cohort which may account for the fact that cardiac involvement was not a significant independent prognostic factor as opposed to liver involvement -the latter accounting for a group of patients who had advanced multi-organ involvement often with poor performance status. While it is again tempting to speculate that clonal biology may have some role to play, it is most likely to reflect a referral bias. It is clear that a haematologic response independently predicts for better survival in most AL series 3, 45 and the complete responders appear to have even better outcomes especially for cases with cardiac involvement 46 . In the current series, although survival of haematologic responders was not statistically better than non-responders, there was a distinct impression that in a small number of responders benefit might well become evident with more prolonged follow-up beyond 50 months.
The former is likely to be accounted by the poor overall response rate of only 32% with no complete responses. In a small number of later cases, the Kaplan-Meier survival curves began to diverge later -consistent with the well recognized phenomenon that regression of AL amyloid and clinical benefit can occur very slowly after suppression of the underlying clonal disorder. The poor haematological response also led to only a limited number of organ responses and was not enough to prevent early deaths for those with advanced organ dysfunction -a clear case in need for rapidly effective therapeutic approaches. However, a majority of the surviving haematologic
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The adequacy of the haematologic response for achieving an organ response may be a complete clonal response in some cases while others may well achieve the same functional improvement with a good partial response 
